Minimal residual disease (MRD) is the minority of cancer cells that still linger in the body after therapy and can potentially cause recurrence. The seminar "Minimal Residual Disease" is dedicated to detection, follow-up, and management strategies to enhance long-term patient outcome.".
Technical progress with sensitive diagnostic methods, such as flow cytometry, PCR, and next-generation sequencing, enables clinicians to identify MRD below detectable levels with standard approaches. Prognostication of relapse and evaluation of treatment effect depends on precise MRD measurement.
This session also addresses how MRD monitoring is applied in hematologic malignancies, solid tumors, and expanding uses throughout oncology. Customized treatment approaches, including dosing the intensity of therapy or starting targeted intervention, can be based on MRD status to hinder recurrence while limiting unnecessary toxicity.
Participants will learn about the clinical importance of MRD, existing detection technologies, and novel solutions for incorporating MRD monitoring into clinical practice. This session highlights the value of early and accurate detection of residual disease in informing treatment choices, enhancing patient prognosis, and promoting personalized oncology.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
